The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series
Authors:
Open Access
- 17 December 2021
- Vol. 7 (1) , 100374
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
- Merck Sharp and Dohme United Kingdom
- Pfizer
- Les Laboratories Pierre Fabre
- AstraZeneca
- Gilead UK and Ireland Corporate Contributions
- Bayer
- Vifor Pharma
- Teva Pharmaceutical Industries
- Novartis
- PharmaMar
- Roche
- Ipsen
- Sanofi
- Gilead Sciences
- Bristol-Myers Squibb
- European Society for Medical Oncology
- Merck
- Servier
- GlaxoSmithKline
This publication has 25 references indexed in Scilit:
- The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling studyThe Lancet Oncology, 2020
- Oncology Nursing During a Pandemic: Critical Reflections in the Context of COVID-19Seminars in Oncology Nursing, 2020
- The impact of the COVID-19 pandemic on cancer careNature Cancer, 2020
- COVID-19: impact on cancer workforce and delivery of careThe Lancet Oncology, 2020
- Let’s address burnout in oncologists and reimagine the way we workNature Reviews Clinical Oncology, 2018
- From Burnout to Resilience: An Update for OncologistsAmerican Society of Clinical Oncology Educational Book, 2018
- Ability of a 9-Item Well-Being Index to Identify Distress and Stratify Quality of Life in US WorkersJournal of Occupational and Environmental Medicine, 2016
- Ability of the Physician Well-Being Index to Identify Residents in DistressJournal of Graduate Medical Education, 2014
- Utility of a Brief Screening Tool to Identify Physicians in DistressJournal of General Internal Medicine, 2012
- The Psychological Impact of the SARS Epidemic on Hospital Employees in China: Exposure, Risk Perception, and Altruistic Acceptance of RiskThe Canadian Journal of Psychiatry, 2009